Health

Healthcare Access and Treatment Advances

Updated 2026-09-08 11:40 UTC 1 source Neutral

Access to a new pancreatic cancer treatment is delayed due to administrative issues. Meanwhile, Inhibrx claims success in developing an immunotherapy target.

Coverage timeline — 2 articles
STAT News
“Pushing this is like a rock up a hill, because there’s been so much failure in the space,” said Inhibrx CEO Mark Lappe.
2026-09-08 11:30 UTC
STAT News
A new wave of illegal fruity vapes, more and more kids on GLP-1s, and other health news from Morning Rounds
2026-09-08 11:32 UTC
Share: Twitter / X LinkedIn